Drug intelligence / Profile preview

SUIVAC APP

Development stage: Unknown
Lead developer: Dyntec
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SUIVAC APP is an inactivated veterinary vaccine developed by Dyntec for the active immunization of pigs against porcine pleuropneumonia. The vaccine is formulated with inactivated whole cells of *Actinobacillus pleuropneumoniae* (typically including serotypes 2, 9, and 11) along with ApxI, ApxII, and ApxIII toxoids. It is designed to reduce clinical symptoms and lung lesions caused by the pathogen. The vaccine is administered via intramuscular injection and is typically used in a two-dose regimen in piglets or sows to provide protective immunity.

Brand names: SUIVAC APP
Other names: SUIVAC APP inj. ad us. vet.

Targets

ApxI (Actinobacillus pleuropneumoniae ApxI toxin)ApxIII (Actinobacillus pleuropneumoniae RTX-toxin III)ApxII (Actinobacillus pleuropneumoniae RTX toxin II)

Beyond the preview

Go deeper on SUIVAC APP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUIVAC APP.

Explore the full profile